What Factors Are Escalating the Demand Across the Adeno-Associated Virus Vector-Based Gene Therapy Market?

0
0

The increasing prevalence of genetic disorders and the growing adoption of gene therapy have propelled substantial expansion in the AAV vector-based gene therapy domain. According to detailed industry evaluation, the Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market was valued at USD 5.718 billion in 2024 and is projected to reach USD 70.67 billion by 2035, exhibiting a CAGR of 25.68% during the forecast period. AAV1, AAV2, AAV5, AAV6, AAV8, and AAV9 serotypes remain among the most sought-after vector platforms globally due to their low immunogenicity, broad tissue tropism, and ability to deliver therapeutic genes for long-term expression. Furthermore, the rising prevalence of genetic disorders, growing focus on personalized medicine, and supportive government initiatives are broadening the adoption base across hematological malignancies, neurological disorders, cardiovascular diseases, ophthalmic diseases, and oncology.

The market is driven by advancements in gene editing technologies and increasing prevalence of genetic disorders. Key players including Spark Therapeutics, Bayer AG, Novartis AG, Bristol-Myers Squibb, GSK, Pfizer Inc., Sarepta Therapeutics, Astellas Pharma Inc., and UniQure N.V. are actively pursuing product innovations and strategic partnerships. Among the leading players, Biogen stands out as a leader with its approved product Zolgensma for spinal muscular atrophy. Novartis is a significant competitor with its Zolgensma gene therapy for spinal muscular atrophy, the first approved treatment of its kind. In Q4 2024, the FDA approved PTC Therapeutics' Kebilidi, the first AAV gene therapy delivered directly into the brain. Do you think AAV gene therapy will eventually become the standard treatment for genetic disorders?

FAQs

What is the current market size of the AAV vector-based gene therapy market?
The market was valued at USD 5.718 billion in 2024 and is projected to reach USD 70.67 billion by 2035, exhibiting a CAGR of 25.68%.

Which segment dominates the AAV gene therapy market?
AAV9 holds the largest market share by vector serotype, while intravenous administration leads by route. Oncology represents the largest disease type segment.

Who are the key players in the AAV gene therapy market?
Key players include Spark Therapeutics, Bayer AG, Novartis AG, Bristol-Myers Squibb, GSK, Pfizer Inc., Sarepta Therapeutics, Astellas Pharma Inc., and UniQure N.V.

#AAVGeneTherapyMarket #GeneTherapy #GeneticDisorders #PrecisionMedicine #Biotechnology

Căutare
Categorii
Citeste mai mult
Lançamentos & Anúncios
Breaking: Asia Pacific Energy Storage Market Set to Surge by 2035
The Asia Pacific Energy Storage Market is on an impressive growth trajectory, projected to reach...
By Rupali Wankhede 2026-04-13 09:56:18 0 0
Networking
Global Aluminum-extruded Products Market Evaluation: High-Strength Alloys, Precision Components & Clean Energy
The Aluminum-extruded Products Market was valued at US$ 95.55 Billion in 2025 and is projected to...
By Mayra Luee 2026-09-22 09:22:11 0 0
Iniciativas de Impacto
FC 27 Ultimate Team: Best Bundesliga Budget Squad for Beginners
SBCs can be a great source of rewards or a black hole for your coins, depending on how you...
By Anselm Rosseti 2026-09-04 07:43:30 0 0
Jocuri
Don't Lose Your Head: Silksong's Lost Vassal Steel Soul Quest
I\u2019ll be honest with you\u2014Steel Soul Mode in Hollow Knight: Silksong is a masterclass in...
By Xtameem Xtameem 2026-07-20 07:05:33 0 0
Conteúdo Técnico
Spectrum Analyzer Market Industry: The Essential Tool for Modern Signal Analysis
The Spectrum Analyzer Market has become a cornerstone of modern electronics and...
By Akash Vibhute 2026-07-30 09:22:59 0 0